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It is the responsibility of the professional care team to develop an effective 
person-centred Pain Management strategy which appropriately assesses patients, 
analyses the results of the assessment and devises a person centred plan to manage 
pain while allowing the person to remain as independent and functional as possible. 
The medications useful in treating acute pain are similar to those used in treating 
other types of pain. The World Health Organization (WHO) analgesic ladder devel-
oped for treating patients with cancer pain also provides a useful approach to treat 
acute pain. At the lowest level (mild pain) are recommended nonopioid analgesics 
such as paracetamol or/plus nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. 
ibuprophen). Such drugs have an analgesic ceiling; above a certain dose, no further 
analgesia is expected. For moderate pain, are recommended combining paracetamol 
and/or a NSAID with an opioid (a weak opoid). The inclusion of paracetamol limits 
the amount of opoids that should be used within 24 hour period, with many ben-
efits which will be discussed later in the chapter. For severe level of pain, a strong 
opoid such as morphine is a better choice; such opoids have no analgesic ceiling. 
Most postoperative or trauma patients initially respond better to a morphine-equiv-
alent opoid. At the moment when the patient is eating and drinking, a combination 
of oral analgesics including opoids and paracetamol plus/minus NSAID are most of 
the time an adequate choice.
Keywords: pharmacology, pharmacokinetics, doses, effects, interactions,  
side effects
1. Introduction
Pain is inevitable, suffering is optional.
(Dalai Lama)
Pain-related complaints represent as many as 70% of presenting concerns for 
patients in the A&E departments or GP setting [1–3]. A wide variety of options are 
available for the treatment of pain, from which the most known and used are the 
analgesics.
The approach to patients in pain should use a division of pain patients into four 
specific treatment groups: acute pain, chronic pain, recurrent pain and chronic pain 
of malignancy. In this chapter we will address mostly to the acute pain management.
Pain treatment should be initiated promptly, titrated to an acceptable level of 
relief, and continued during the cause’s investigation. It is inappropriate to delay 
analgesics use until a diagnosis has been made. There is no evidence that the admin-
istration of adequate doses of opioid analgesia to establish patient comfort impairs 
the medical ability to rich a diagnose of an emergency condition. To the contrary, 
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administration of analgesia may enhance the accuracy of physical examination and 
patient assessment [4, 5].
The medications useful in treating acute pain are similar to those used in treat-
ing other types of pain [1]. The World Health Organisation (WHO) analgesic ladder 
(Figure 1) developed for treating patients with cancer pain also provides a useful 
approach to treat acute pain. At the lowest level (mild pain) are recommended nono-
pioid analgesics such as paracetamol or/plus nonsteroidal anti-inflammatory drugs 
(NSAIDs) (e.g. ibuprofen). Such drugs have an analgesic ceiling; above a certain dose, 
no further analgesia effect is expected [1]. For moderate pain, are recommended 
combining paracetamol and/or a NSAID with an opioid (a weak opioid). The inclu-
sion of paracetamol limits the amount of opioids that should be used within 24 hour 
period, with many benefits which will be discussed later in the chapter. For severe 
level of pain, a strong opioid such as morphine is a better choice; such opioids have no 
analgesic ceiling. Most postoperative or trauma patients initially respond better to a 
morphine-equivalent opioid. By the moment the patient is eating, drinking and ready 
for discharge, a combination of oral analgesics including opioids and paracetamol 
plus/minus NSAID are most of the time an adequate option.
Not all types of pain respond equally to the same medication. Usually NSAIDs 
and steroids are highly effective in controlling soft tissue and bone pain. Bone pain 
may be helped partially by opioids [1]. But overall, the combination of NSAIDs, 
paracetamol and opioids is synergistic in treating the most types of pain. Opioid 
analgesics are useful in controlling somatic and visceral pain. Neuropathic pain, 
often described as pain with a burning and hyperaesthesia characteristic, which 
responds well to a diverse group of drugs, called adjuvants, including low dose 
of antidepressants (amitriptyline), anticonvulsants (carbamazepine and clon-
azepam), antiarrhythmics (mexiletine), baclofen and alfa-adrenergic agonists 
(clonidine). Opioids may also be helpful [1]. Most of the time, analgesia is improved 
after 1–2 days of using adjuvant drugs. Adjuvants were not developed initially 
as analgesics but recent studies show they poses benefits in a better pain control. 
Drugs that control pain by different mechanisms of action may be synergistic, when 
used together. Also, by lower doses of two or more different agents, the patient may 







2. Nonopioid analgesic agents
2.1 Paracetamol
Paracetamol is the first-line agent for the treatment of both acute and chronic 
pain. It is one of the pain killers with the highest profile of safety and is a first 
pharmacologic option for controlling pain in children and adults. It has a high toxic-
to-therapeutic ratio and has very few significant drug interactions compared with 
other analgesics [2].
It can be given orally, rectally or parentally, has small anti-inflammatory activity, 
and is an effective analgesic and antipyretic.
Although paracetamol has been in use since 1880, its pharmacologic mecha-
nism of action is not fully known. It has a rapid absorption from the small 
intestine after oral administration. Paracetamol has lower protein binding than 
NSAIDs (and hence fewer potential drug interactions) and higher volume of 
distribution [6].
Paracetamol is the active metabolite of the earlier (more toxic) drugs acetanilide 
and phenacetin. The recommended dose in adults is 0.5–1 g oral, iv or rectal every 
4–6 hours when necessary, without exceeding a total daily dose of 4 g [6].
Paracetamol has a CNS action, where inhibits prostaglandin synthesis. In clinical 
doses it has insignificant peripheral anti-inflammatory action. Unlike morphine, 
paracetamol has no apparent biding sites, and unlike NSAIDs it does not inhibit 
peripheral cyclo-oxygenase activity. But however, his mechanisms of action include, 
beside central COX-2 inhibition [2, 7], inhibition of a central cyclo-oxygenase, 
COX-3, that is selectively susceptible to paracetamol, and modulation of descending 
serotonergic pathways that suppresses spinal cord nociceptive transmission. There 
is also evidence of agonism at the cannabinoid receptor CB1 [2, 8]. There are, other 
evidences that paracetamol may inhibit prostaglandin endoperoxidase H2 produc-
tion at the cellular level, independent of cyclooxygenase activity [2, 6].
The most recent Cochrane review [9] of RCTs of single-dose oral analgesic for 
acute postoperative pain in adults reported a NNT of 3·6 with 1 g paracetamol, 
when morphine 10 mg IM has 2.9, ibuprofen 400 mg - 2.4 and codeine 60 mg - 16.7. 
Efficiency of paracetamol is improved in combinations with other analgesics, such 
as 400 mg ibuprofen, 60 mg codeine and 10 mg oxycodone (NNT 1·5, 2·2 and 1·8 
respectively) [6, 9].
So, paracetamol is an effective analgesic, with potency somewhat less than 
standard dose of morphine. Paracetamol is an efficient adjunct to opioid analgesia, 
and regular administration after surgery produce an opioid sparing effect, because 
reduce opioid requirements by 20–30%. Paracetamol proved to be an integral 
component of multimodal analgesia in combination with NSAIDs and opioids. 
Paracetamol has less side effects than the NSAIDs and can be used when the latter 
are contraindicated.
A significant concern regarding paracetamol use relates to the development of 
hepatotoxicity; however, current data suggest this is unlikely to develop at thera-
peutic doses [10]. However, doses of more than 150 mg/kg of paracetamol taken 
within 24 hours may result in severe liver damage, hypoglycaemia and acute tubular 
necrosis, especially when associated with dehydration and chronic malnutrition 
[11]. Individuals taking enzyme-inducing agents are more susceptible. So, impor-
tant caution should be taken in overdoses due to the risk of liver damage and less 
frequently renal damage. Nausea and vomiting, the only early features of poisoning, 
usually settle within 24 hours. Persistence beyond this time, often associated with 
the onset of a right-side subcostal pain and tenderness, usually indicates develop-
ment of hepatic necrosis.
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Paracetamol is metabolised in the liver primarily through conjugation to 
sulphate or glucuronides [2]. A minor pathway for the oxidative metabolism of 
paracetamol produces the toxic metabolite N-acetyl-P-benzoquinone (NAPQI) [2]. 
NAPQI requires glutathione for detoxification and elimination. Hepatic toxicity 
can occur when glutathione pathways are overwhelmed by an increase in NAPQI or 
decrease in glutathione.
Paracetamol is generally well tolerated with rare side effects when the right doses 
are prescribed (Table 1) [2, 4].
2.2 Interactions
It is associated with several important drug interactions. Many anticonvulsants, 
including phenytoin, barbiturates and carbamazepine induces hepatic microsomal 
enzymes. Increased conversion of paracetamol to its toxic metabolite may occur in 
patients who are taking anticonvulsants, but this rarely leads to concerning conse-
quences in the context of the usual doses for pain management [2, 6].
Although uncommon, drug interaction resulting in an increased INR is reported 
for patients taking both paracetamol and warfarin, particularly among patients taking 
high doses of paracetamol (> 9 g/week) [2, 12, 13]. Long term use of paracetamol 
should be avoided in patients with hepatic or renal impairment. Patients with a his-
tory of salicylate hypersensitivity characterised by urticaria have a 11% cross-reactiv-
ity to paracetamol, and the agent should be used with caution in this group [2, 7].
3. Nonsteroidal anti-inflammatory drugs
The NSAIDs share several properties with aspirin and may be considered together.
NSAIDs are particularly used for the treatment of patients with chronic disease 
accompanied by pain and inflammation.
Some of them are also used for acute pain management and in the short-term 
treatment of mild to moderate pain including transient musculoskeletal pain. They 
are also suitable for the pain control in dysmenorrhoea and to release pain caused by 
secondary bone tumours, many of which produce lysis of bone and increase prosta-
glandins synthesis. Many of the NSAIDs are also used for postoperative analgesia as 
part of the multimodal analgesia strategy. Selective inhibitors of COX2 may be used 
in preference to non-selective NSAIDs for patients at high risk of developing serious 
gastro-intestinal side-effects.
There are some limited and low quality evidences against the use of NSAIDs in 
bone pathology, suggesting that prostaglandins promote bone formation and that 
NSAID might impair this process [14, 15], theory not proven through properly 
Side effects Rare Frequency not known





• Toxic epidermal necrolysis
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thrombocytopenia as is bone marrow suppression
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conducted studies. There is no evidence that NSAIDs administration on short term 
after fracture is detrimental to healing [2].
3.1 Mechanism of action
3.1.1 Prostaglandin synthesis inhibition
These agents inhibit cyclooxygenase (COX) and, as result, the synthesis of 
prostaglandin, a key mediator of inflammation, in the peripheral tissues, CNS and 
nerves – leading to an effective raise in the threshold of nociceptors stimulation. 
Aspirin acetylates and irreversibly inhibits cyclo-oxygenase, while NSAIDs work 
by competitive inhibition, being reversible. The prostaglandins are part of the 
eicosanoid’s family, oxygenated metabolites of arachidonic acid and other polyun-
saturated fatty acids that include leukotrienes [6].
The rate of prostaglandin synthesis is usually low, being regulated by trauma 
and tissue stimuli, which activates phospholipases to free arachidonic acid, from 
which prostaglandins are produced. Prostaglandins have several physiological 
roles, including gastric mucosal protection, bronchodilation and maintenance of 
renal tubular function, renal vasodilatation, regulation of tubular electrolytes and 
modulation the action of renal hormones [2, 6]. The side effects on the renal system 
of chronic NSAIDs is well known. In certain clinical settings when there are high 
plasma concentration of the vasoconstrictors rennin, noradrenaline, angiotensin 
and vasopressin, intrarenal vasodilators including prostacyclin are produced and 
renal function can be affected by NSAIDs administration [2]. The concomitant 
use of other potential nephrotoxic drugs, such as gentamicin, can worsen the renal 
effect of these drugs [2]. Nevertheless, with careful patient selection and closed 
monitoring the incidence of NSAID-renal damage is low.
Triggering bronchospasm is a recognised phenomenon in patients with asthma, 
rhinitis and nasal polyps [2]. Such “aspirin induce asthma” can be severe, and goes 
up to 10–15% as incidence with a feature cross sensitivity with NSAIDs. A known 
history of aspirin induce asthma should band the administration of NSAIDs periop-
eratively. The mechanism is unclear, but practice shown the reaction increases with 
the potency of the COX inhibition [2].
Endothelial released prostacyclin induces vasodilatation and prevents platelet 
adhesion, and platelet thromboxane produces aggregation and vasospasm. In addition 
to prostaglandins, cyclooxygenase induces prostacyclin synthesis, a vasodilator that also 
increases GI mucosal perfusion. Also, in the gastric tissue, COX-1 increases mucus and 
bicarbonate production, valuable feature for stomach mucosal protection [2]. Inhibition 
of COX-1 is affecting this protection, predisposing to ulcerations and bleeding, which 
can be exacerbated by concomitant NSAID-induced platelet dysfunction [2].
3.1.2 Cyclo-oxygenase isoenzymes
Two subtypes of cyclo-oxygenase enzyme have been identified. These are con-
stitutional COX-1 and inducible COX-2, the last one triggered by inflammation and 
trauma. The COX-1 is present in all cells and regulates various roles in homeostatic 
function. NSAIDs, like aspirin, are non-selective cyclo-oxygenase inhibitors that act 
on both COX-1 and COX-2, which results in multiple beneficial effects (reduction in 
inflammation, pain and fever) but also some important side effects.
These two COX isoenzymes have 75% aminoacid homology, with almost identi-
cal enzymes kinetics.
COX-1 is a membrane bound haemoglycoprotein found in the endoplasmic retic-
ulum of prostaglandin-inducing cells. The COX active site is a long hydrophobic 
Pain Management - Practices, Novel Therapies and Bioactives
6
channel. NSAIDs block COX-1 halfway down the channel by hydrogen bounding 
in a reversible fashion. Aspirin acetylates serine, irreversibly preventing access for 
arachidonic acid [6].
COX-2 has similar sites to COX-1 for the attachment of arachidonic acid, and a 
similar three-dimensional structure to COX-1.
Under physiological condition COX-1 activity predominates, to produce 
prostaglandins that regulate rapid physiological responses such as vascular homeo-
stasis, gastric function, platelet activity and renal function. The concentration 
of the COX-1 isoenzyme is low, but it may increase 2 to 4-fold, triggered by grow 
hormones and various hormones stimulation. Low concentration of COX-2 can 
normally be detected in the brain, kidney and the pregnant uterus. COX-2 mRNA 
expression by synovial cells, fibroblasts, monocytes may be increased 10 to 80-fold 
when stimulated by cytokines, bacterial lipopolysaccharides or growth factors [6] 
These triggers increase COX-2 synthesis and tissue PGE2 concentration, resulting in 
inflammation and pain.
Inhibition of COX-1 induces antiplatelet activity that might be cardioprotec-
tive by inhibition of thromboxane synthesis more than prostacyclin. Inhibition of 
COX-2 inhibits prostacyclin synthesis more than thromboxane and may induce 
prothrombotic effects, leading to a higher risk of cardiovascular events [2]. In the 
case of nonselective COX inhibitors, both effects appear to be in balance each other 
out, resulting in minimal changes in cardiovascular risk [2]. But instead, the action 
of COX-2 inhibitors may result in result in an increased cardiovascular risk [16, 17].
Prostaglandins released by COX-1 is also a factor on keeping a good glomeru-
lar filtration rate (GFR) by renal vasodilatation that maintain renal blood flow. 
Inhibition of COX-1, especially in dehydrated patients can lead to affect GFR 
and even to an acute kidney injury [2]. Other condition that might worsen under 
NSAIDs treatment is congestive heart failure, due to sodium and water retention, 
hyperkalaemia, hypertension and acute renal failure.
The most common adverse effect of NSAIDs is GI mucosal erosion. In patients 
taking chronic NSAIDs (continuously for 1 year) 10 to 60% will experience 
abdominal pain, nausea, dyspepsia, and a 2 to 4% will end up with a symptomatic 
peptic ulcers [18]. Between the risk factors are known: age, concomitant use of 
corticosteroids and warfarin, coronary artery disease, congestive heart failure and 
diabetes mellitus. Several studies proved the efficiency of some protective agents as 
misoprostol and proton pump inhibitors [19]. The relative risk for causing GI effects 
under the NSAIDs treatment are shown in Table 2 on below.
3.2 Side effects
This category of drugs is widely used, being very efficient medicines, but respon-
sible for more serious drugs-related side effects than any other class of analgesic 
drugs [20]. The main side effect of NSAIDs as stated earlier is gastric erosion with 
the risk of GI bleeding, but also platelets dysfunction, renal failure and anaphylaxis 
or bronchospasm in individuals who have “aspirin – induced asthma” [2].
Single dose of NSAIDs such as diclofenac and ketorolac inhibit platelet function 
(prolong skin bleeding time and inhibit platelet function in vitro), but do not tend 
to increase bleeding in normal patients. However, when concomitant anticoagula-
tion treatment or presence of subclinical bleeding diathesis occurs, then there is an 
increased risk of surgical bleeding [2].
Conversely, NSAIDs and COX-2 inhibitors have a small prothrombotic tendency. 
The risk is increasing by prolonged administration and by the dose taken, and for the 
more selective agents (COX-2) but also for diclofenac [2]. Studies shows that diclof-




represents a high risk for thrombosis. But reduced doses to 1200 mg a day Ibuprofen 
and Naproxen 1 g daily are not associated with an increase risk [21, 22].
3.3 Contraindications of NSAIDs
There are many contraindications of this drug class presented on below  
(Table 3) [23].
3.4 Efficiency of the NSAIDs
The number needed to treat (NNT, basically the number of patients in a study to 
whom the drug must be given to show a benefit) for diclofenac 50 mg 2.3, ketorolac 
10 mg is 2.6 and ibuprofen 400 mg 2.4. For comparison, the NNT of morphine 10 mg 













Risk of serious gastrointestinal effects of NSAIDs [18, 19].
Relative contraindications Absolute contraindication
Impaired hepatic function, diabetes, bleeding or coagulation 
disorder, vascular disease
History of GI bleeding or ulceration
Surgery with a high risk of intraoperative haemorrhage 
(cardiac, vascular, etc.)
Known allergy to NSAIDs
Surgery where an absence of bleeding is important (eye surgery 
or neurosurgery)
Sever liver dysfunction
Cardiac failure (risk of sodium, 
potassium and water retention)
Concurrent use of ACE inhibitors, potassium sparing diuretics, 
anticoagulants, methotrexate, cyclosporin, gentamicin
Dehydration, hypovolemia, hypotension
Pregnant and lactating women Hyperkalaemia
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NSAIDs COX-2
Efficacy for moderate to 
severe acute pain (numbers 







Renal function Can impair renal function postoperatively Similar adverse effects 
Gastrointestinal Acute gastrointestinal damage and bleeding 
can occur. Risk increased with higher doses, 





Platelet function Inhibit platelet function but do not 
significantly increase surgical blood loss 
in normal patients. Associated with higher 
incidence of post-tonsillectomy bleeding




10–15% of asthmatics affected when given 
aspirin. Cross-sensitivity with NSAIDs
Do not produces 
bronchospasm
Bone healing Impaired in animal studies. No strong 
evidences that clinically important
Similar to NSAIDs
Table 4. 
Comparison of non-selective NSAIDs and COX-2 inhibitors.
IM is 2.9 and codeine 60 mg PO is 16.7. When given in combination with opioids, 
NSAIDs optimise the pain control and decrease opioid consumption by 25–50% [2]. 
NSAIDs are insufficient as a single pain killer use for relief of very severe pain.
COX-2 inhibitors produce less clinically significant peptic ulceration than other 
NSAIDs. So, COX-2 inhibitors are not far from any incidence of this adverse event, 
and there still debates on COX-2 inhibitors use in patients who have various risk fac-
tors for gastric erosion.
Platelets do not produce COX-2 (only COX-1) and so, COX-2 selective inhibitors do 
not affect platelet function. Studies have proved the lack of and antiplatelet effect of 
COX-2 inhibitors, and a reduction in surgical bleeding in comparison to other NSAIDs.
COX-2 is resident (constitutive) in some tissues including the renal, and COX-2 
inhibitors have similar adverse effects on renal function to the non-selective 
NSAIDs (Table 4) [2].
3.5 Drug interactions
Aspirin. NSAIDs may impair the cardioprotective feature of aspirin, but this 
subject is still debatable lacking of strong evidences against use of NSAIDs for acute 
pain or inflammation in a patient on chronic daily aspirin use [24, 25].
Oral Anticoagulants. NSAIDs have an antiplatelet effect, added to the anticoagu-
lant properties of warfarin, is exponential increasing the risk of significant bleeding 
complications, especially from the GI ulcers. Furthermore, NSAIDs displace protein-
bound warfarin and is leading to increase the prothrombin times during a constant 
warfarin dose [18]. NSAIDs should be avoided in patients who are taking warfarin.
ACE Inhibitors. Concomitant use of NSAIDs with ACE inhibitors may impair 
kidney function and may prejudice the antihypertensive effect of ACE inhibitors.
Diuretics. Patients on diuretics have a higher risk of developing renal failure 
because of NSAIDs-mediated decreased kidney blood perfusion. Also, the natriuretic 
response to diuretics is in relation with prostaglandin-mediated vasodilatation.
Glucocorticoids. Patients on corticosteroids possess a higher risk of peptic ulcer. 





Lithium. NSAIDs increase lithium reabsorption and may reduce lithium excre-
tion, and cause subsequently increases lithium levels. CNS manifestations (confu-
sion, drowsiness, vertigo, tremors, seizures), QRS complex widening and cardiac 
arrhythmias are warning signs of lithium toxicity. The lithium doses should be 
reduced in patient concurrently taking NSAIDs.
Methotrexate. Chronic use of NSAIDs and methotrexate have resulted in pro-
longed, increased levels of methotrexate, leading to severe toxicity. A possible 
mechanism is accountable due to decreased renal blood supply, slowing down the 
elimination of methotrexate.
4. Opioid analgesic agents
In 1680, Sydenham wrote “Among the remedies it has pleased Almighty God to 
give to man to relive his suffering, none is so universal and so efficacious as opium” 
[2, 26]. Hundreds of years later, this statement is still valid, and opioids are the 
cornerstone of pain management. The beneficial effects have been well studied for 
centuries, as their toxicity and also the potential for abuse.
Opioid analgesics are usually used to relieve moderate to severe pain particularly 
of visceral origin. Repeated administration may cause dependence and tolerance, 
but this is not deterrent in the pain control of terminal illness. Regular use of a 
potent opioid may be appropriate for certain cases of chronic non-malignant pain; 
treatment should be supervised by medical staff and the patient should be assessed 
regularly. However, due to concerns about inducing opioid toxicity or addiction and 
sometimes due to poor understanding of the pharmacology features of these drugs, 
opioids are often inadequate used in clinical practice [27, 28].
4.1 Mechanism of action and toxic effects
Opioids bind to specific endorphin system receptors located throughout the 
nervous system but not only. Opioid receptors are G-protein-coupled transmem-
brane receptors. These exist throughout the CNS, with particularly high concentra-
tion in thalamus and spinal cord. They are also present outside the CNS, and these 
are responsible for other opioids effects (gastrointestinal tract) and their postulated 
value in some peripheral anaesthetic techniques, such as intra-articular infiltrations 
[6]. The actions of various opioids are induced by the specific binding properties of 
the agent to the various receptors (Table 5).
Opioid receptor 
class
Effects Associated endogenous 
endorphin
Miu 1 Euphoria, supraspinal analgesia, confusion, dizziness, 
nausea, low addiction potential
Beta-endorphin
Miu 2 Respiratory depression, CV and GI effects, miosis, 
urinary retention
Beta-endorphin
Delta Spinal analgesia, CV depressions, decreased brain and 
myocardial activity, physical dependence
Enkephalin
Kappa Spinal analgesia, dysphoria, psychotomimetic effects, 




Gamma Dysphoria, psychotomimetic effects Beta-endorphin
Table 5. 
Opioids receptors end their effects.
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Opioids decrease the medullary sensitivity to CO2, which may cause respiratory 
depression and also, suppress the medullary cough centre, for this reason some 
studies advocate for its use as an antitussive. Opioids can activate the chemoreceptor 
trigger zone, causing nausea or vomiting, but this is relatively infrequent. This drug 
class decrease bowel motility and smooth muscle function, responsible for consti-
pation, and rarely, urinary retention. To a varying degree, some opioids destabilise 
mast cells in a dose dependent fashion, causing histamine release, manifested with 
pruritus, urticaria and sometimes, orthostatic hypotension.
4.2 Clinical effect
Opioid agonist agents cause a range of mainly depressant and some stimulant 
actions of the CNS through specific receptors (Table 6). These drugs have little 
capacity to produce amnesia, do not alter seizure threshold and have no anticonvul-
sant activity [6].
Opioids given systemically produce analgesia through actions at two anatomi-
cally distinct regions: supraspinal and spinal sites. They efficiently reduce the 
intensity of pain and the associated fear. This is achieved by raising the pain 
threshold, modifying the reaction to pain, and inducing sleep. They are efficient for 
controlling dull pain rather than sharp intermittent pain. Opioids are less effective 
for the treatment of neuropathic pain.
Opioids actions are also towards reduction in the level of consciousness and 
eventually produce sleep, with the loss of responsiveness to verbal stimulation. 
In anaesthesia combinations, they produce a dose related decrease in the MAC 
for volatile anaesthetics, with a ceiling of 60–70% decrease in MAC [6]. Another 
important feature in the combination with the volatile agents is increase in cerebral 
vasoconstriction [6]. Opioids do not cause a loss of cerebral autoregulation or 
reactivity to CO2. During EEC recording, there is a ceiling effect, with a slowing 
EEG frequency and the production of high-voltage (delta) waves [6].
4.3 Cardiovascular effects
In normovolemic patients, opioids barely influence haemodynamic param-
eters, with minimal cardiac depression, no baroreceptors inhibitions and modest 
reduction in preload and afterload. Haemodynamic compromise may be detected 
in subjects whose cardiovascular integrity is dependable on a high level of sym-
pathetic tone, because opioids decrease central sympathetic outflow when even 
small doses can cause hypotension and circulatory collapse [6]. Morphine has 
the greatest effect on the vascular system. Morphine has the greatest effect on 
histamine release and subsequent indirect effect on catecholamine release. This 
may lead to tachycardia with a reduction in systemic vascular resistance (SVR) and 
mean arterial pressure (MAP). This risk can be prevented by pre-treatment with 
an antihistaminic drug and volume loading [6].
Opioids induce a negative chronotropic effect through a central vagal stimula-
tion. Pethidine, however, has a homology with atropine and can trigger tachycardia, 
and it is the only opioid to induce significant direct myocardial depression when 
used at high doses. Myocardial depression is observed also after extraordinary high 
doses of morphine and fentanyl, as during cardiovascular anaesthesia. Morphine 
has indirect positive inotropic effects at doses of 1–2 mg/kg, and blocks neurally 
and hormonally mediated venoconstriction to reduce preload, rendering it useful in 
the management of left ventricular failure [6].





4.4 Effects on other organ systems
Opioids are the most efficient of all pain analgesics drugs for attenuating the 
stress response associated with pain, laryngoscopy and airway manipulation. The 
plasma concentration of stress hormones (cortisol, catecholamines, vasopressin, 
aldosterone and growth factor) increases during trauma, anaesthesia or surgery. 
This produce increased myocardial work, tissue catabolism and hyperglycae-
mia – effects associated with increased morbidity and mortality. Opioids reduce 
nociception inhibiting the pituitary-adrenal axis, decreasing central sympathetic 
outflow and influencing centrally mediated neuroendocrine response. Fentanyl 
and its congeners are the most efficacious in this action (Table 7).
System Effect
Musculoskeletal Gait Decrease physical performance
Ataxia
Decrease spinal cord reflexes
Rigidity Muscular rigidity occurs 60–90 seconds post-injection and 
abolish after 10–20 minutes
Mainly thoracoabdominal and arms muscles, higher risk 
with advanced age, high speed of injection, increased dose, 
use of N2O
Mediated via nucleus raphe magnus
Multifocal 
myoclonus
Non-convulsive related, higher risk with pethidine
Neural Central Spectrum from abnormal eye movement, to contraction of 
extremities, to tonic-clonic movements
Euphoria: especially for opioids which cross the blood-
brain barrier quickly
Dysphoria in some individuals
Subjective feelings of body warmth and heavy extremities
Apathy
Decreased level of consciousness
Decreased concentration and orientation
EEG Effects vary between different opioids: slowing of 
frequency, production of high voltage & waves




Miosis (via a decrease in inhibition to the nucleus) except 
pethidine
Reversed by hypoxia and atropine
Cerebrovascular SSEPs No effect
ICP No effect
CBF No effect, but increased vasoconstriction with vasodilators
No loss of autoregulation or CO2 reactivity
CMRO2 reduced by up to 10–25%




Promote hypothermia via decreased BMR (10–20%), 
venodilation, muscle relaxation
SSEPs – somatosensory evoked potential, ICP – intracranial pressure, CMRO2 – cerebral metabolic rate of oxygen 
consumption.
Table 6. 
Opioids effects on the CNS [6].
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System Effect
Cardiovascular Heart rate Sinus bradycardia via central vagal stimulation
Occasionally sinus arrest exacerbated by concomitant vagal 
excitation (e.g. laryngoscopy) and Beta-blockers
Mean arterial 
pressure
Usually no effect or a slight decrease (unless significant 
bradycardia)
Greater decrease if associated with histamine release
Vascular system No effect on SVR (unless histamine release)
Mild venodilation with a decrease in preload (due to decrease of 
central sympathetic outflow)
Myocardium No effect on contractility (except for pethidine which is a 
depressant)
No effect on metabolic rate
Possible ischemic preconditioning
Excitability Decreased myocardial contractility
Increased refractory period
Increased VF threshold
Respiratory Mechanics Decrease in rate, tidal volume and minute ventilation at 
equianalgesic doses
Increase pauses, irregular breathing and apnoea
Control Increased apnoeic threshold
Decrease CO2 sensitivity
Decrease carotid body chemoreception and hypoxic drive
Voluntary control of respiration remains intact
No effect on hypoxic pulmonary vasoconstriction
Airway reflexes Decrease airway reflexes with improve tolerance to ETT
Antitussive through central and peripheral actions
Decrease mucociliary action
Brief cough in up to 50% with pethidine bolus
Gastrointestinal Stomach and 
bowel
Decrease peristalsis and secretions and increase tone causing dry 
stool and constipation
Decrease gastric acid
Decrease gastric emptying with increase antral tone and decrease 
lower oesophageal sphincter tone promoting high aspiration risk
Increase tone of pyloric, ileocecal and anal sphincters
Biliary tree Increase bile duct pressure




Genitourinary Kidney Antidiuresis as a result of decrease in renal blood flow and 
decrease in GFR (predominates)
Decrease vasopressin release in response to osmotic triggers
Bladder Increased bladder and urethral tone
Vesicular sphincter contraction
Immunity Immune system Decrease immunoglobulin production (uncertain significance)
Reactivation of herpes simplex virus 2–5 days after neuraxial 
opioid
Table 7. 
Opioid effects on major organ system [6].
4.5 Side effects
Side effects can be observed from minors to the most concerning ones and are 




dysfunction, concurrent administration of certain drugs, route of administration 
and prior of opioid exposure. Some side effects induced by the opioids are induced 
by the activation of the opioid receptors either peripherally or centrally, or even in 
both areas. Serious allergic reactions to opioids are extremely rare, although ana-
phylaxis has been reported.
At equianalgesic doses, all opioids produce equivalent degrees of respiratory 
depression through reducing the sensitivity to CO2 of the breathing drive. The 
extreme ages, elderly and neonates are at the highest risk. Tolerance arises rapidly to 
this effect, and with chronic opioid exposure the risk of major respiratory depression 
is reduced. Apnoea may occur in conscious patients, but this is rare, and is usually 
associated with other signs of CNS depression. In such a condition, apnoeic patients 
can be instructed to breath as voluntary control of ventilation remains intact. Sleep or 
the concomitant use of other CNS depressants (except clonidine) potentiates this risk.
Opioid-induce depression of airway reflexes is usually regarded as an advan-
tage side effect for the practitioner in some condition like airway manipulation. 
Although at the same time the mucociliary function depression can be detrimental. 
All opioids have an antitussive activity at less than analgesic doses, working via 
central and peripheral mechanisms.
The incidence of nausea after opioids use is reported to be between 10 and 60%, 
and this is markedly increased in pain-free and ambulatory patients (via opioid 
sensitisation of the vestibular nucleus). This reactivity is based on  individual 
variability, but tolerance develops rapidly [6]. Switch to oral administration and 
substituting one opioid to another may reduce the incidence of nausea.
Constipation remains the most common side effect of chronic opioid treatment, 
and toxic megacolon may occur in patients with ulcerative colitis [6]. Tolerance, 
in this situation develops very slowly, as well as other smooth muscle effects. 
Loperamide is a synthetic agent, does not cross the blood brain barrier, used as 
an antimotility drug. All opioids are reported to increase bile duct pressure, with 
a spasmogenic action cause contraction of the sphincter of Oddi with effects on 
doses dependent activity [6]. Pethidine also, produces smooth muscle contraction 
via a direct action. Opioids effects on the biliary tract can be reversed by naloxone, 
nitroglycerine and glucagon.
Other effects on the smooth muscle target the genitourinary system, often 
leading to urinary retention and urgency. This effect is predominant in elderly and 
when administered neuraxially. This later feature explains a centrally mediated 
mechanism of action via receptors located at the sacral spinal cord.
There are some others centrally mediated opioids effects. Some of these are 
of no clinical benefit and usually unpleasant. Often, opioids may trigger pruritus 
with various ranges of severity, with mechanism of action not fully discovered. The 
pruritus predominantly affects nose, face and chest being independent of histamine 
release. Substituting opioids agents will decrease the incidence. Studies has shown 
that low dose of naloxone will alleviate this effect. Muscle rigidity is triggered at 
or just after the loss of consciousness and may manifest from hoarseness in mild 
cases to impossibility of ventilate in severe situations. It can be minimised by 
co-administration of induction agents and benzodiazepines. In anaesthetic practice 
may be prevented by pre-treatment priming with small doses of muscle relaxants. 
This side effect was reported to be with a higher incidence on concomitant use of 
nitrous oxide [6]. It is seen more commonly with Fentanyl and its congeners than 
with morphine and the risk is dose depended. In emergency situation of impossibil-
ity of ventilation can be reversed by administration of naloxone.
Opioids agents decrease thermoregulation thresholds, except pethidine, which is 
a unique in its ability to reduce shivering. Tramadol also has proved to be efficacious 
in this regard [6].
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Histamine release and associated hypotension are variable in incidence and 
severity, and are with decreased incidence where is a slow IV administration and 
ameliorated by intravascular fluid loading. This effect is less with fentanyl and its 
subclass agents, except pethidine. The histamine release may be localised or gener-
alised, often causing facial flushing and variable itch [6].
4.5.1 Opioid-specific effects
Pethidine has been described as a unique agent because of its non-opioid 
effects. It has a local anaesthetic effect of equivalent potency to cocaine and it 
has a quinidine-like effect on cardiac muscle to reduce cardiac irritability and 
arrhythmias [6]. Pethidine overdose produce a complex syndrome characterised 
by a cardiovascular collapse, seizures, hyperreflexia, mydriasis in addition to a 
 respiratory depression [6].
The use of phenylpiperidines family (except remifentanil) in anaesthesia has 
been associated with postoperative respiratory depression after high doses, due 
secondary peaks in plasma levels, possible from the opioids release from the body 




The choice of route of administration depends on the opioid being utilised, pain 
severity, the need for agent titration, potential side effects and contraindications 
to a particular route. The way of administration may activate the onset of peak 
analgesia and the side effects. For example, respiratory depression may be trig-
gered 7 minutes after an IV dose of morphine, but not until 30 minutes after IM or 
6–10 hours after a spinal administration.
There are various degree and length of pain relief effect conferred by certain 
routes. Spinal administration may produce a greater quality and potentially a lon-
ger duration of analgesia, with a lower incident of supraspinal effects. However, 
an increased incidence of specific side effects (nausea, itching, urinary reten-
tion) occurs.
No opioid agonist demonstrates dose-dependent pharmacokinetics. First pass 
metabolism of orally administrated opioids is made in the liver and the digestive 
tract wall (up to 50%). Opioids given IM or SC have 100% bioavailability, but peak 
plasma concentration may be variable up to fivefold influenced by body tempera-
ture, site of injection and hemodynamic status. IV administration results in a much 
restricted rage of plasma concentration [6].
The lung exerts an important first-pass effect on highly lipid-soluble opioids. Prior 
administration of other lipophilic amines, such propranolol decreases pulmonary 
uptake, by saturating biding sites [6].
4.6.2 Elimination
Opioids mainly sustain a liver metabolism with a renal excretion of the more 
hydrophilic metabolites. A few metabolites also take the biliary excretion route. 
Some amounts of the more hydrophilic agents may be excreted unchanged in the 
urine. Liver blood flow is the main factor influencing the plasma clearance for most 




Morphine. The biotransformation of morphine is unique among opioids agents. 
Glucuronidation is responsible for 60–80% of its metabolism, and is primarily 
undergone in the liver with production of high quantity morphine-3-glucoronide 
(M3G) and only 10% of morphine-6-glucoronide (M6G). The remainder undergoes 
sulphation (important feature in neonates where glucuronidation metabolism is 
immature), 5% is demethylated to normorphine, a small amount is converted to 
codeine, and 10% is excreted in the urine [6, 29]. In healthy subjects up to 10% of 
glucuronidation occurs in extrahepatic sites, such kidney and intestine. The excre-
tion of the morphine metabolites is directly influenced by the creatinine clearance. 
90% of conjugated morphine is excreted in the urine and 10% is excreted in bile, 
sweat and breast milk. M6G is 2–4 time more potent than morphine and has a 
longer elimination half-life [29]. Despite being more hydrophilic than morphine, 
M6G cross the blood-brain barrier, with a longer action due to slower elimination 
from this site. There is also an entero-hepatic recirculation of morphine and its 
metabolites, particularly under the chronic oral administration [29].
Diamorphine. Diamorphine is inactive and needs deacetylation in the CSF, liver, 
and plasma to its final metabolites 6-monoacetylmorphine and morphine. These 
active metabolites are more hydrophilic, and their ensuing metabolism is as for 
morphine [6].
Codeine. Codeine is suffering a hepatic metabolization to mainly codeine conjugates 
and norcodeine, with some urinary excretion of free codeine. Up to 10% of a dose 
is also metabolised to morphine. This biotransformation is responsible for analgesia 
produced by codeine. Due to genetic polymorphism, up to 8% of western Europeans 
are deficient of the enzyme implicated in the liver metabolism. These patients require 
higher doses, and they may still not experience effective pain relief. Furthermore, the 
variability may produce dangerous high morphine levels in breast milk [30].
Pethidine. Pethidine metabolism mainly involves hydrolysis to pethidinic acid, 
with small amount being freely excreted through urine (5%) of the prodrug – 
although this may be increased up to 25% with urinary acidification (pH < 5) [6]. 
One third of the metabolism takes the route to N-demethylation to norpethidine, 
which is finally hydrolysed to norpethidinic acid. Enzyme induction triggered by 
chronic pethidine use (sometimes also by carbamazepine therapy) induces high 
levels of transformed norpethidine [6].
Fentanyl and sufentanyl. The high lipid solubility of these agents is responsible for 
their large volume of distribution, which causes rapid and continued peripheral tis-
sue uptake, limiting initial liver metabolism. This is leading to a greater variability 
in plasma concentration (13-fold range in fentanyl) during the elimination phase, 
particularly with fluctuations in muscles blood flow that may be responsible of the 
secondary peaks in plasma concentration after large doses. Fentanyl, sufentanyl and 
alfentanyl have a small unchanged renal excretion, being mainly metabolised in the 
liver. These inactive metabolites are taking the urinary route for excretion.
4.6.3 Patient factors influencing opioid pharmacokinetics and pharmacodynamics
The pharmacokinetics and dynamics of opioids may be altered in a number of 
physiological states as stated in Table 8.
4.7 Opioid drug interaction
This class of pain killers have limited but important interactions with other drugs. 
Their action is synergistically with other CNS depressant on the level of conscious-
ness. Barbiturates, benzodiazepines and propofol produce effects on the loss of 
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consciousness with a synergic action from the opioids side and also increase the risk of 
cardiovascular depression. With anaesthetic use, opioids may decrease the concentra-
tion of volatile agents by up to 50% while ensuring amnesia and immobility, with the 
preservation of hemodynamic stability at low inhaled concentrations (≤1 MAC) [6].
The use of opioids (particularly pethidine and tramadol) with monoamine 
oxidase inhibitors (MAOI) may lead to serious and potentially fatal consequences 
as excitatory syndrome (type I) [2, 6]. This is complex syndrome characterised 
by excitatory phenomena including agitation, fever, rigidity, seizures and coma. 
This is triggered by the excessive CNS serotonin activity, since both MAOI and 
pethidine block serotonin reuptake. Rarely also can arise an inhibitory syndrome 
(type II) characterised by respiratory depression, coma and hypotension, which is 
the result of MAOI inhibition of hepatic microsomal enzymes leading to a pethidine 
accumulation.
A similar excitatory syndrome (serotoninergic) is found during the combination 
of tramadol and serotonin-noradrenaline reuptake inhibitors (SNRIs) [6].
Morphine has been recommended as the opioid of choice for use in these patients.
4.8 Opioid antagonists
The main opioid antagonist currently used in practice is naloxone.
Naloxone is an N-allyl derivate of oxymorphone. It is pure opioid antagonist, 
without an intrinsic pharmacological activity. It has a high affinity for miu opioid 
receptors but also blocks other receptors. Naloxone reverses the respiratory depres-
sion and analgesia of opioids but also precipitates the withdrawal syndrome in 
opioids addicts. Naloxone could also block the action of endogenous opioids. IV 




Obesity Overdosage Central volume of distribution is not reflected by 
actual body weight
Increased volume of distribution prolongs 
elimination half-life
Infant Prolonged effect Decreased conjugation capacity
Immature renal function
Elderly Increased sensitivity to 
opioid
Decreased neuronal cell mass
Decreased central volume of distribution
Prolonged effect of infusion Decreased lean body mass with increase adipose 
tissue is responsible for an increase in total volume of 
distribution
Decreased hepatic blood flow (by 40–50% by age  
of 75)
Hepatic failure Increased sensitivity to 
opioids (in severe liver failure 
only)
Synergism if encephalopathic
Altered integrity of blood-brain barrier
Increased elimination half-life for pethidine and 
tramadol
Renal failure Morphine toxicity Accumulation of M6G
Possible hydrolysis of glucuronides back to parent 
compound
Uraemia potentiates CNS depression and increases 
blood-brain barrier permeability
Table 8. 




but incremental titration (1.5–3 mcg/kg) is referable in order to minimise the 
reversal of the analgesic effects of the opioids. Naloxone’s action time is roughly 
30 minutes, so further doses may be considered to avoid the return of respira-
tory depression effects of any agonist agent that outlasts the effect of naloxone. 
Naloxone is also efficient in releasing the pruritus and urinary retention of the 
intrathecal and epidural opioids. Naloxone has very small oral availability, only 2%, 
because and major first pass metabolism [6].
4.9 Tramadol
Tramadol is included in the opioids class of drugs, with unique and complex 
mode of action, only part of which is mediated through opioid receptors. Tramadol 
is an analogue of codeine and acts as a weak agonist at all types of opioid receptors, 
with some preference for the miu receptors. It has 10% of the potency of morphine. 
Tramadol blocks the reuptake of noradrenaline and 5-HT (serotonin) and facilitate 
the release of the later. By its effects, influences nociceptive transmission activating 
the descending inhibitory pathways in the CNS. Therefore, Naloxone only partially 
reverses the analgesic effects of tramadol. Effects on alfa2-adrenergic, NMDA and 
benzodiazepine receptors may be due to indirect effects secondary noradrenergic 
system effects [31].
Tramadol is recommended in the treatment of moderate to severe pain. It is well 
absorbed when given orally, with a bioavailability of 68% and only 20% protein 
bound. Tramadol is predominantly metabolised in the liver by demethylation and con-
jugation, with 90% being excreted in the urine. The elimination half-life is 4–6 hours. 
His metabolites have longer half-life (up to 9 hours) and 2–4 times greater analgesic 
potency than tramadol and precautions should be taken in hepatic and renal failure.
Tramadol exhibits small risk for respiratory depression when compared with 
equianalgesic doses of morphine. Also, cardiovascular effects are minimal. There 
is a low potency for abuse and physical dependence, but still reported. Tramadol’s 
known side effects include: dizziness, nausea, sedation, dry mouth, sweating and 
skin rashes.
Concomitant use of MAOIs is contraindicated and co-administration with 
carbamazepine may decrease the concentration and effect of tramadol.
5. General pain management principles
• A - ask about pain regularly
• B - believe the patient’s/resident’s and family’s reports of pain and what  
relieves it
• C - choose appropriate pain control options
• D - deliver interventions in a timely, logical and coordinated fashion
• E - empower patients
6. Pharmacological intervention
As a result of a nationwide effort to reduce unnecessary opioid use and reduce 
incidents of patient abuse, clinicians are encouraged to carefully assess their 
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patient’s pain, limit the number of prescribed opioids analgesics and limit further 
prescribing by evaluating the patient’s pain relief and increased functional ability.
The trend to lower usage has had a tremendous impact on opiod use worldwide 
over the last years. By 2016, paracetamol/hydrocodone, which had been the lead-
ing medication prescribed for pain, had dropped from first most prescribed pain 
medication to the fourth most prescribed drug in the nation, with the volume of 
prescriptions down to 7.2% in 2015, from 34% in 2012.
In order to facilitate this continuing trend, it is recommended that the following 
WHO decision ladder and in-depth patient assessment be utilised before requesting 
or prescribing opioid compounds.
7. Multimodal analgesia
Multimodal analgesia is defined as the use of more than one pharmacological 
class of analgesic medication targeting different receptors along the pain pathway 
with the goal of improving analgesia while reducing individual class-related side 
effects. Evidence today supports the routine use of multimodal analgesia in the 
perioperative period to eliminate the over-reliance on opioids for pain control and 
to reduce opioid-related adverse events. A multimodal analgesic protocol should 
be surgery-specific, functioning more like a checklist than a recipe, with options to 
tailor to the individual patient.
Elements of this protocol may include opioids, non-opioid systemic analgesics 
like paracetamol, non-steroidal anti-inflammatory drugs, gabapentins, ketamine, 
and local anaesthetics administered by infiltration, regional block, or the intra-
venous route [32–37]. While implementation of multimodal analgesic protocols 
perioperatively is recommended as an intervention to decrease the prevalence of 
long-term opioid use following surgery, the concurrent crisis of drug shortages 
presents an additional challenge. Anaesthesiologists and acute pain medicine 
specialists will need to advocate locally and nationally to ensure a steady supply of 
analgesic medications and in-class alternatives for their patients’ perioperative pain 
management.
8. Conclusion
The recommendations are on the basis of the underlying premise that optimal 
management begins with the patient assessment and development of a plan of care 
tailored to the individual and the medical status or the surgical procedure involved, 
with follow-up assessments and adjustments as needed. The evidences support the 
use of multimodal regimens in many situations, although the exact components of 
effective multimodal care will vary depending on the patient, setting, and surgi-
cal procedure or the medical condition. Therefore, it is important that clinicians 
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